Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences announced on May 28, 2026, the initiation of a Phase I clinical study evaluating an oral solid dose formulation developed using artificial intelligence — what the Nottingham-based integrated CRDMO describes as the first AI-designed drug formulation to reach human clinical evaluation, according to PR Newswire.

The study began at the company's UK facility following clearance from the Medicines and Healthcare products Regulatory Agency, as reported by Drug Discovery World. Healthy volunteers will be enrolled to assess the formulation's safety and pharmacokinetics, with a stated objective of validating AI as a tool for drug product development decisions.

From algorithm to clinic

The formulation was produced using an advanced machine learning algorithm developed by Intrepid Labs, applied alongside Quotient Sciences' proprietary Translational Pharmaceutics platform, according to PR Newswire. Together, the two systems enabled rapid exploration of formulation options and more data-informed optimization of expected clinical performance before physical experiments began.

Traditional formulation development relies on iterative empirical cycles — adjusting excipients, stability parameters, and delivery mechanisms through successive rounds of physical testing. AI-driven approaches compress that process by predicting optimal configurations computationally, with the potential to reduce both time and material costs in early development.

This program marks a significant advancement in harnessing the power of advanced machine learning alongside deep scientific expertise to streamline drug development. This approach, coupled with our Translational Pharmaceutics® platform, enables our customers to make earlier, more informed decisions with greater confidence, ultimately increasing the likelihood of clinical success. — Andy Lewis, Chief Scientific Officer, Quotient Sciences

What the milestone means for the CDMO sector

Quotient Sciences operates as a contract research, development, and manufacturing organization, meaning the methodology's implications extend well beyond a single asset. PharmaSource notes that the study represents part of a broader company strategy to integrate AI-enabled approaches across formulation development and clinical workflows, with further data and updates expected in the coming months.

For biotech and pharmaceutical sponsors evaluating CDMO partners, the ability to offer AI-assisted formulation services is increasingly a differentiator — particularly for complex molecules where formulation challenges have historically driven late-stage attrition. Demonstrating that an AI-formulated compound can clear regulatory review for human testing strengthens the commercial case for embedding such tools into standard development workflows.

The CDMO and CRO sectors face sustained pressure to shorten development cycles and improve first-time-right rates for clients. An AI-driven formulation approach that reduces upfront experimental burden could address both priorities simultaneously, though clinical attrition rates across the industry remain high regardless of how a compound was prepared.

AI's expanding role in drug development

Until now, AI's most prominent contributions to pharmaceutical R&D have centered on target identification, molecular screening, and protein structure prediction. Applying machine learning directly to formulation design — determining how an active compound is physically stabilized and delivered — represents a meaningful step further along the development chain.

MarketScale notes that the broader biotech sector is in what industry observers characterize as a builder phase, in which leading organizations are not simply running AI pilots alongside existing workflows but rebuilding their data environments to support continuous AI integration. The Quotient Sciences program fits that pattern: the company has framed this Phase I study as the opening move in a multi-program AI integration strategy, not a standalone experiment.

The company said it expects to share additional data as it advances and expands its AI-enabled capabilities, according to PR Newswire. Whether the formulation itself succeeds clinically is a separate question — but establishing that an AI-designed formulation can earn regulatory approval for human testing gives the field a proof-of-concept data point it did not previously have.